#hta — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #hta, aggregated by home.social.
-
WHO pharmacovigilance reform is pushing safety evidence teams toward smarter RWE, AI-enabled signal workflows, and clearer regulatory evidence plans. https://www.mattheneus.com/editorial/who-smart-pharmacovigilance-rwe-ai-safety-evidence-strategy-2026-05-24 #HTA #RWE #RegulatoryAffairs
-
The WHA teleradiology resolution turns remote imaging services into an evidence, governance, and implementation-readiness question for market access teams. https://www.mattheneus.com/editorial/who-teleradiology-resolution-evidence-plan-2026-05-22 #HTA #EvidenceSynthesis #RegulatoryAffairs
-
Dutch drug assessment timelines are tightening, raising the bar for reimbursement dossier readiness and evidence planning. https://www.mattheneus.com/editorial/zin-sluis-drug-assessment-timelines-2025-faster-reimbursement-dossiers-2026-05-04 #HTA #Pharma #RegulatoryAffairs
-
TLV’s Myalepta decision shows how rare-disease flexibility still needs subgroup value, severity, and negotiated cost to support reimbursement. https://www.mattheneus.com/editorial/tlv-myalepta-generalised-lipodystrophy-limited-reimbursement-2026-04-25 #HTA #Pharma #RegulatoryAffairs
-
Sweden’s TLV framed Vevizye as a restricted reimbursement case: comparable effect to Ikervis, equal daily medicine cost, and no implied superiority claim. https://www.mattheneus.com/editorial/tlv-vevizye-ciclosporin-limited-reimbursement-ikervis-cost-comparison-2026-04-28 #HTA #Pharma #RegulatoryAffairs
-
Trial retention is now an HTA evidence-governance issue: missing outcomes can weaken comparative estimates, utility inputs, and reimbursement models. https://www.mattheneus.com/editorial/trial-retention-outcome-data-completeness-hta-evidence-governance-playbook-2026-04-22 #HTA #NMA #MAIC #EvidenceSynthesis #RegulatoryAffairs
-
Gold rush for APL member gardens at Harrogate Spring Flower Show https://www.allforgardening.com/1736328/gold-rush-for-apl-member-gardens-at-harrogate-spring-flower-show/ #APL #garden #HarrogateSpringFlowerFestival #HTA
-
Gold rush for APL member gardens at Harrogate Spring Flower Show https://www.allforgardening.com/1736328/gold-rush-for-apl-member-gardens-at-harrogate-spring-flower-show/ #APL #garden #HarrogateSpringFlowerFestival #HTA
-
Target trial emulation is getting harder to ignore in HTA: registry-based RWD shifted the ICER for post-first-line RA biologics from ~£34.7k to ~£46.8k/QALY. https://www.mattheneus.com/editorial/target-trial-emulation-rwd-cost-effectiveness-hta-playbook-2026-04-03 #HTA #RWE #HealthEconomics
-
CAR-T access is no longer just a clinical story; HTA timing and cost-effectiveness design now shape who gets to market and when.
-
The UK just made non-animal evidence planning more real: MHRA’s new advance Module 4 review route gives teams an earlier read on whether their package will hold up. https://www.mattheneus.com/editorial/mhra-non-animal-methods-module-4-advance-review-guidance-2026-04-02 #HTA #RegulatoryAffairs #Pharma
-
HTA evidence teams are hitting a fragmentation wall: ITC, MAIC, NMA, RWE, modelling, and reporting now need one traceable workflow, not stitched-together handoffs. https://www.mattheneus.com/editorial/abangelabs-hta-studio-itc-foundation-end-to-end-hta-evidence-platform-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis #HealthEconomics
-
HTA submissions keep breaking where comparative evidence meets the economic model. If the lineage is not traceable, cost-effectiveness and budget-impact claims turn fragile fast. https://www.mattheneus.com/editorial/hta-submissions-comparative-evidence-economic-model-lineage-problem-2026-04-02 #HTA #HealthEconomics #RegulatoryAffairs
-
HTA capacity doesn't scale through one-off pilots—it compounds through repeatable evidence, methods, and governance across countries. https://www.mattheneus.com/editorial/eastern-europe-central-asia-hta-capacity-building-governance-playbook-2026-04-02 #HTA #HealthEconomics #RegulatoryAffairs
-
Germany’s Long/Post-COVID Annex VI move shows how weak comparative evidence can still reshape reimbursable care pathways when unmet need is high. https://www.mattheneus.com/editorial/g-ba-long-post-covid-annex-vi-off-label-four-drugs-evidence-lineage-2026-04-02 #HTA #EvidenceSynthesis #HealthEconomics
-
Four placebo-controlled trials showing no benefit is exactly the kind of evidence reset that changes payer and regulator narratives fast. https://www.mattheneus.com/editorial/ema-tecovirimat-siga-mpox-restriction-four-rcts-no-benefit-2026-03-26 #HTA #RegulatoryAffairs #Pharma
-
G-BA says concizumab's added benefit is not proven in haemophilia A because comparator alignment still decides whether evidence lands or unravels. https://www.mattheneus.com/editorial/g-ba-concizumab-haemophilia-a-added-benefit-not-proven-comparator-mismatch-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis
-
NICE’s fezolinetant decision is a live case study in how reimbursement can clear despite uncertain indirect evidence beyond placebo. The real lesson is comparator-bridge discipline, not false certainty. https://www.mattheneus.com/editorial/nice-fezolinetant-menopause-final-guidance-indirect-comparison-uncertainty-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis #RegulatoryAffairs
-
Under-5 utility evidence is no longer a side quest—if infant/toddler HRQoL is weak, the cost-effectiveness model is fragile from day one. https://www.mattheneus.com/editorial/infant-toddler-utility-measurement-cost-effectiveness-governance-playbook-2026-04-02 #HTA #HealthEconomics #Pharma
-
RWE fails when it is treated as a late appendix instead of submission architecture. Canada and EU HTA now reward early evidence planning and traceable decision logic. https://www.mattheneus.com/editorial/rwe-submission-architecture-canada-eu-hta-evidence-planning-playbook-2026-04-01 #HTA #RWE #RegulatoryAffairs #EvidenceSynthesis
-
AI can already speed up evidence screening and extraction, but the latest validation signal says HTA teams should keep human oversight on judgment-heavy risk-of-bias work. https://www.mattheneus.com/editorial/ai-evidence-synthesis-validation-coverage-gap-playbook-2026-04-01 #HTA #EvidenceSynthesis #Pharma
-
When two NMAs disagree, the ranking usually isn’t the truth—it’s the output of study selection, population splits, and consistency choices. This playbook shows how to stress-test the decision question before a league table enters a dossier. https://www.mattheneus.com/editorial/when-two-nmas-disagree-similarity-consistency-governance-playbook-2026-04-01 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
-
PBAC’s blinatumomab listing amendment shows how fast evidence lineage can alter reimbursement scope in ALL. https://www.mattheneus.com/editorial/pbac-blinatumomab-pre-b-cell-all-listing-amendment-d-alba-lineage-2026-03-14 #HTA #Pharma #RegulatoryAffairs
-
NICE’s EQ-5D-5L value-set shift just changed the ground rules for 2026 cost-effectiveness submissions. https://www.mattheneus.com/editorial/nice-eq5d-5l-value-set-modular-update-cost-effectiveness-governance-playbook-2026-03-29 #HTA #HealthEconomics #RegulatoryAffairs
-
Single-arm evidence can price in uncertainty unless HTA assumptions are explicitly governed. https://www.mattheneus.com/editorial/gene-therapy-single-arm-hta-economic-evidence-playbook-2026-03-27 #HTA #MAIC #HealthEconomics #RegulatoryAffairs
-
Cyber resilience is becoming part of regulatory readiness, not just an IT problem. https://www.mattheneus.com/editorial/mhra-supply-chain-cyber-security-evidence-operations-playbook-2026-03-01 #HTA #Pharma #RegulatoryAffairs
-
AMNOG haemophilia dossiers get much harder when inhibitor and non-inhibitor populations are split—this playbook explains the evidence architecture teams need before review. https://www.mattheneus.com/editorial/amnog-haemophilia-split-population-evidence-architecture-inhibitor-stratification-playbook-2026-03-26 #HTA #EvidenceSynthesis #RegulatoryAffairs
-
EMA’s positive opinion for Fubelv signals another biosimilar evidence-lineage milestone in Europe—and a useful read on how regulatory decisions translate into market-access context. https://www.mattheneus.com/editorial/ema-fubelv-positive-opinion-etanercept-biosimilar-evidence-lineage-2026-02-26 #HTA #Pharma #RegulatoryAffairs
-
G-BA finds no added benefit for ixekizumab in paediatric enthesitis-associated arthritis after comparator-relevance review.
-
HAS France NMA Acceptability Framework: A Cross-Agency Evidence Planning Playbook.
-
NICE's New EQ-5D-5L Value Set: What It Means for QALY Utility Measurement and Cost-Effectiveness Submissions.
-
What NICE TA1142 Reveals About Biomarker-Stratified Evidence Standards and Stopping-Rule Design for First-in-Class Biologics.
-
Bridging HAS and IQWiG Evidence Standards: A Cross-Border Network Meta-Analysis Planning Playbook.
-
MHRA's patient-information modernisation and device advice refresh set a new evidence-operations baseline.
-
EMA Management Board ePI roadmap turns product-information governance into an HTA evidence operations priority.
-
NMA outputs are now shaping HTA timelines before submission—not after. If your evidence plan starts late, your access strategy starts behind. https://www.mattheneus.com/editorial/hta-value-nma-projections-evidence #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
-
Governance gets stronger when patient and consumer voice is formalized early in HTA. https://www.mattheneus.com/editorial/hta-consumer-panel-governance-playbook-singapore-ace-2026-03-29 #HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis
-
Retractions can silently invalidate NMA assumptions days before dossier lock—if your evidence ops aren’t retraction-aware, you’re flying blind. New seven-day governance playbook: https://www.mattheneus.com/editorial/nma-retraction-ingestion-governance-playbook-2026-03-29 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
-
EMA weekly PIP and PSUSA cadence is now an evidence-maintenance signal, not admin noise. https://www.mattheneus.com/editorial/ema-pip-psusa-weekly-cadence-evidence-maintenance-playbook-2026-03-10 #HTA #MAIC #EvidenceSynthesis #RegulatoryAffairs
-
CEE HTA bodies like Poland's AOTMiT face a dual challenge: aligning domestic benefit-assessment methodology with EU JCA evidence standards for ITC & NMA while preserving reimbursement integrity. A practical playbook for market-access teams.
https://www.mattheneus.com/editorial/aotmit-poland-itc-nma-eu-jca-evidence-standards-cee-market-access-playbook-2026-03-27
#HTA #NMA #EvidenceSynthesis #RegulatoryAffairs -
Publication bias is systematically under-tested in NMA dossiers — a scoping review of 22 critical appraisal instruments confirms no standardised decision rules exist. Comparison-adjusted funnel plots should be mandatory in HTA submissions: https://www.mattheneus.com/editorial/fallback-canary-publication-bias-nma-comparison-adjusted-funnel-plot-playbook-2026-03-28 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
-
When certainty grades diverge, first-order loops often reveal where NMA confidence can break.
https://www.mattheneus.com/editorial/grade-dominant-first-order-loop-nma-certainty-evidence-cinema-2026-03-27
#HTA #NMA #EvidenceSynthesis -
CADTH Reimbursement Reviews: ITC and NMA Evidence Standards for Canadian Market Access. https://www.mattheneus.com/editorial/cadth-reimbursement-review-itc-nma-evidence-standards-canada-market-access-playbook-2026-03-26 #HTA #NMA #MAIC #EvidenceSynthesis #Pharma
-
Non-Proportional Hazards in Network Meta-Analysis: A Five-Step Governance Protocol for Time-to-Event HTA Submissions. https://www.mattheneus.com/editorial/fallback-canary-non-proportional-hazards-nma-tte-governance-playbook-2026-03-25 #HTA #NMA #EvidenceSynthesis #Pharma
-
G-BA Approves LDCT Lung Cancer Screening for German Statutory Health Insurance from April 2026
https://www.mattheneus.com/editorial/g-ba-ldct-lung-cancer-screening-statutory-health-insurance-germany-2026-03-13
#HTA #NMA #RegulatoryAffairs #EvidenceSynthesis -
Top-journal NMA quality gaps now demand transitivity-first governance in HTA evidence programs
-
Adaptive trial outputs are colliding with economic modelling timelines: an HTA evidence governance playbook https://www.mattheneus.com/editorial/adaptive-trial-to-economic-model-lineage-hta-evidence-governance-playbook-2026-03-23 #HTA #NMA #MAIC #HealthEconomics #EvidenceSynthesis
-
Cross-country HTA evidence transfer is now a credibility bottleneck: a new 2026 review finds inverse-odds weighting dominates practice while true transportability remains limited. What’s your governance plan for target-population assumptions? https://www.mattheneus.com/editorial/hta-transportability-iosw-cross-country-evidence-transfer-playbook-2026-03-23 #HTA #MAIC #NMA #EvidenceSynthesis #RWE
-
G-BA’s March closure wave and new NMA quality data point to a stricter comparator-governance era
-
IQWiG reports added benefit not proven for lisocabtagene maraleucel in relapsed or refractory mantle cell lymphoma. https://www.mattheneus.com/editorial/iqwig-lisocabtagene-maraleucel-mcl-added-benefit-not-proven-unanchored-maic-2026-03-16 #HTA #MAIC #EvidenceSynthesis #Pharma